COVID-19 vaccines: early success and remaining challenges

Naor Bar-Zeev; Tom Inglesby

doi:10.1016/S0140-6736(20)31867-5

COVID-19 vaccines: early success and remaining challenges

Naor Bar-Zeev, Tom Inglesby

Bloomberg School of Public Health

Research output: Contribution to journal › Comment/debate › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	868-869
Number of pages	2
Journal	The Lancet
Volume	396
Issue number	10255
DOIs	https://doi.org/10.1016/S0140-6736(20)31867-5
State	Published - Sep 26 2020

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(20)31867-5

Cite this

@article{1fbd7d0713224be0b28ba32c02cbde30,

title = "COVID-19 vaccines: early success and remaining challenges",

author = "Naor Bar-Zeev and Tom Inglesby",

year = "2020",

month = sep,

day = "26",

doi = "10.1016/S0140-6736(20)31867-5",

language = "English (US)",

volume = "396",

pages = "868--869",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10255",

}

TY - JOUR

T1 - COVID-19 vaccines

T2 - early success and remaining challenges

AU - Bar-Zeev, Naor

AU - Inglesby, Tom

PY - 2020/9/26

Y1 - 2020/9/26

UR - http://www.scopus.com/inward/record.url?scp=85091075789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091075789&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(20)31867-5

DO - 10.1016/S0140-6736(20)31867-5

M3 - Comment/debate

C2 - 32896290

AN - SCOPUS:85091075789

SN - 0140-6736

VL - 396

SP - 868

EP - 869

JO - The Lancet

JF - The Lancet

IS - 10255

ER -

COVID-19 vaccines: early success and remaining challenges

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this